BACKGROUND Allopurinol is an effective urate-lowering drug that is well tolerated by the majority of patients. Patients with chronic renal insufficiency have an increased risk of hypersensitivity reactions with allopurinol. CASE PRESENTATION 75 year old male patient with gout, renal insufficiency, history of metastatic colorectal carcinoma status post-resection was referred to Allergy clinic ...

AIMS To evaluate the effects of allopurinol in lens induced uveitis (LIU) by morphological methods and to compare these effects with those of steroids and a combination of both drugs biochemically and morphologically. METHODS Lipid peroxides (LPO) of the retinal tissue were determined by two different methods (thiobarbituric acid assay (TBA) and high performance liquid chromatography expresse...

Gout is an often forgotten disease, despite being the most common inflammatory arthritis in adults in the Western world. Lesinurad, a new urate-lowering therapy (ULT), is now approved for the treatment of gout in the USA and the European Union, 6 and is in phase III programmes as a combination therapy in many other countries. Lesinurad is a selective inhibitor of urate/anion exchanger 1 and org...

SUBJECT The concentration of serum uric acid (SUA) is one of the potential markers of cardiovascular and cerebrovascular diseases, as well as some other severe diseases. In this pharmacological - clinical study we evaluated allopurinol effect on certain values of lipid profile fractions in hyperuricemic patients diagnosed with metabolic syndrome that had pronounced cardiovascular problems, also...

Treatment options for gout are well established and reasonably effective. They include anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids and colchicine and urate-lowering therapies such as allopurinol and probenecid. However, despite the availability of effective urate-lowering therapy, there remains a subset of patients with gout who, despite aggr...

Standard therapy in the United States for malignancy-associated hyperuricemia consists of hydration, alkalinization, and allopurinol. Urate oxidase catalyzes the enzymatic oxidation of uric acid to a 5 times increased urine soluble product, allantoin. Rasburicase is a new recombinant form of urate oxidase available for clinical evaluation. This multicenter randomized trial compared allopurinol ...

OBJECTIVES While studies have suggested that gout and hyperuricaemia are associated with the risk of premature death, none has investigated the role of urate-lowering therapy on this critical outcome. We examined the impact of allopurinol, the most commonly used urate-lowering drug, on the risk of mortality in hyperuricaemic patients. METHODS From a population of hyperuricaemic veterans of [s...

*Corresponding author: Prof. Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran. Email: [email protected] Implication for health policy/practice/research/medical education: It is well known that hyperuricemia is an independent risk factor for renal progression in IgA nephropathy, however it is unclear the effect of al...

BACKGROUND AND AIMS Allopurinol has been presented as a safe and effective adjunct to thiopurine therapy in inflammatory bowel disease (IBD). We aimed to determine the rate of infectious complications and clinical successes with a combination of thiopurine/allopurinol in IBD, and to identify which variables predict 6-thioguanine, 6-methylmercaptopurine, and white blood cell levels. Additionally...

Over the years, allopurinol has been widely used as the preferred choice of urate lowering therapy in patients with gout. However, its role in patients with renal impairment is limited; and adverse reactions are well documented. Febuxostat, a newer oral non-purine xanthine oxidase inhibitor has been proven in several trials to be more effective and tolerable compared to allopurinol and may be u...